Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Equity Income (2023 - 2025)

Perspective Therapeutics (CATX) has disclosed Equity Income for 3 consecutive years, with -$1000.0 as the latest value for Q4 2025.

  • Quarterly Equity Income rose 50.0% to -$1000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2000.0 through Dec 2025, up 75.0% year-over-year, with the annual reading at -$2000.0 for FY2025, 75.0% up from the prior year.
  • Equity Income hit -$1000.0 in Q4 2025 for Perspective Therapeutics, roughly flat from -$1000.0 in the prior quarter.
  • In the past five years, Equity Income ranged from a high of -$1000.0 in Q1 2025 to a low of -$12000.0 in Q3 2023.
  • Historically, Equity Income has averaged -$3857.1 across 3 years, with a median of -$2000.0 in 2024.
  • Biggest five-year swings in Equity Income: surged 60.0% in 2024 and later soared 50.0% in 2025.
  • Year by year, Equity Income stood at -$5000.0 in 2023, then soared by 60.0% to -$2000.0 in 2024, then skyrocketed by 50.0% to -$1000.0 in 2025.
  • Business Quant data shows Equity Income for CATX at -$1000.0 in Q4 2025, -$1000.0 in Q1 2025, and -$2000.0 in Q4 2024.